Biosimilars | Emerging Biosimilars | Truxima/Rixathon Launch Tracker | Germany | Wave 2 | 2018
Truxima (rituximab), Celltrion’s MabThera biosimilar, became the first oncology monoclonal antibody biosimilar to enter the European market in April 2017. Two months later, Sandoz’s Rixathon, a second MabThera biosimilar, launched in Europe. In this series, we track awareness and uptake of Truxima and Rixathon since launch, to understand how their entry will impact the NHL, CLL, and immune biologics market. Along with awareness, familiarity, and perception of Truxima and Rixathon, our analysis also looks at the drivers and barriers behind uptake of these agents. Promotional efforts are explored, as well as prescriber and nonprescriber profiles, and benchmarking against other biosimilars, to better understand the dynamics of the German biosimilars market.
Questions Answered:
- Are German physicians aware of Truxima and Rixathon?
- What are the drivers to prescribing Truxima and Rixathon? What is the current level of Truxima and Rixathon use, and how is that changing over time?
- Has experience with Truxima and Rixathon changed physicians’ opinion of biosimilars?
- Have physicians experienced pressure to prescribe Truxima and Rixathon to patients?
- What promotional messages are sales representatives employing for Truxima, Rixathon, and MabThera?
